TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7981574

Group type: EXPERIMENTAL
Intervention: GH response to GHRH in Alzheimer's disease (n = 28)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: GH response to GHRH in parkinsonism with dementia (n = 10)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: GH response to GHRH in progressive supranuclear palsy with dementia (n = 10)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: GH response to GHRH in dementia of vascular origin (n = 28)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: TSH response to TRH in Alzheimer's disease (n = 28)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: TSH response to TRH in parkinsonism with dementia (n = 10)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: TSH response to TRH in progressive supranuclear palsy with dementia (n = 10)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: TSH response to TRH in dementia of vascular origin (n = 28)
Number of subjects: 86
Study: 31501293

Group type: EXPERIMENTAL
Intervention: Peritoneal ultrafiltration (PuF) with 1 overnight exchange using Icodextrin dialysate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Continuation of conventional HF treatment
Number of subjects: 10
Study: 27915068

Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound therapy (1W/cm2, pulsed: 1:5)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (intensity: zero)
Number of subjects: 12
Study: 26779673

Group type: EXPERIMENTAL
Intervention: Holistic facial composite construction by participant-witnesses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no composite construction)
Number of subjects: 0
Study: 25173550

Group type: EXPERIMENTAL
Intervention: SB predilation
Number of subjects: 372

Group type: COMPARATOR
Intervention: No predilation
Number of subjects: 372
Study: 23176246

Group type: EXPERIMENTAL
Intervention: Higher plane of nutrition (HPN; 0.30 Mcal intake energy/kg of metabolic body weight using a 28% protein‐20% fat milk replacer)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Higher plane of nutrition (HPN)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional nutrition (CN; 0.13 Mcal intake energy/kg of metabolic body weight using a 20% protein‐20% fat milk replacer)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional nutrition (CN)
Number of subjects: 20
Study: 19464709

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PXF) 1200 mg daily for 12 months
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PXF)
Number of subjects: 34
Study: 16409425

Group type: EXPERIMENTAL
Intervention: 3-weekly regimen of gemcitabine (1000 mg/qm, days 1 and 8) and paclitaxel (175 mg/qm, day 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 2-weekly regimen of gemcitabine (1250 mg/qm, day 1) and paclitaxel (120 mg/qm, day 2)
Number of subjects: 30
Study: 15281431

Group type: EXPERIMENTAL
Intervention: IFN-gamma-1b 200 microg sc
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Colchicine 1 mg qd plus prednisone 10 mg qd
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 10
Study: 11284782

Group type: EXPERIMENTAL
Intervention: Alosetron 0.5 mg b.d.
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Alosetron 1.0 mg b.d.
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Alosetron 2.0 mg b.d.
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 9253567

Group type: EXPERIMENTAL
Intervention: Sufentanil (0.3 microgram kg‐1 i.v.) added in group 2
Number of subjects: 18

Group type: COMPARATOR
Intervention: Desflurane administration in both groups
Number of subjects: 18
Study: 8432597

Group type: EXPERIMENTAL
Intervention: Salmonella typhi Ty21a vaccine
Number of subjects: 634

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 634
Study: 3567001

Group type: EXPERIMENTAL
Intervention: Salbutamol 200 micrograms aerosol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aminophylline 670 mg (high-dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (aerosol and infusion)
Number of subjects: 0
Study: 29371859

Group type: EXPERIMENTAL
Intervention: Cigarette smoking under the influence of alcohol
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cigarette smoking under the influence of marijuana
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Perceived pleasure from smoking cigarettes when drinking alcohol
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Perceived pleasure from smoking cigarettes when using marijuana
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cigarette smokers who used alcohol + marijuana
Number of subjects: 200
Study: 27633173

Group type: EXPERIMENTAL
Intervention: LP0132-fermented juice
Number of subjects: 33

Group type: COMPARATOR
Intervention: Unfermented citrus juice (placebo)
Number of subjects: 33
Study: 24763840

Group type: EXPERIMENTAL
Intervention: Clonidine (150 μg) plus 9 mL of saline
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lignocaine (10 mL of 2% lignocaine with adrenaline 1:200,000)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Ropivacaine alone (20 mL of 0.75% ropivacaine)
Number of subjects: 75
Study: 22155931

Group type: EXPERIMENTAL
Intervention: Normobaric hypoxic breathing simulating 4100 m altitude
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Return to normoxia
Number of subjects: 10
Study: 19916742

Group type: EXPERIMENTAL
Intervention: Carboplatin and cetuximab
Number of subjects: 0
Study: 18281266

Group type: EXPERIMENTAL
Intervention: 3 MU s.c. of IFNalpha2a three times a week for 2 years (Arm A)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Combined treatment with 3 MU s.c. of IFNalpha2a plus DTIC 850 mg/m(2) every 4‐8 weeks for 2 years (Arm B)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Observation alone (Arm C)
Number of subjects: 444
Study: 15979016

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS) treatment
Number of subjects: 29
Study: 12437432

Group type: EXPERIMENTAL
Intervention: Cymetra
Number of subjects: 44

Group type: COMPARATOR
Intervention: Zyplast
Number of subjects: 44
Study: 10515401

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg twice daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 7674318

Group type: EXPERIMENTAL
Intervention: Highly predictive genetic test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New trials including persons at very high risk of developing cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized trial
Number of subjects: 0
Study: 1651856

Group type: EXPERIMENTAL
Intervention: pipecuronium 45 micrograms kg‐1
Number of subjects: 90

Group type: COMPARATOR
Intervention: pancuronium 60 micrograms kg‐1
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: pipecuronium 70 micrograms kg‐1
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: pipecuronium (both doses)
Number of subjects: 90
Study: 7451732

Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Waking analgesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: No analgesia (control)
Number of subjects: 40
Study: 30977520

Group type: EXPERIMENTAL
Intervention: Fremanezumab
Number of subjects: 2566

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2566
Study: 29519686

Group type: EXPERIMENTAL
Intervention: Tangzhiqing tablet (TZQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nuciferine and paeoniflorin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27258301

Group type: EXPERIMENTAL
Intervention: PRISE (5-6 meals/day at 2.0 g/kg BW/day)
Number of subjects: 30
Study: 24191977

Group type: EXPERIMENTAL
Intervention: Morphological awareness intervention (8-week program, 4 times a week, 25 min per session)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Morphological awareness intervention
Number of subjects: 75
Study: 22237854

Group type: EXPERIMENTAL
Intervention: 6 mg aripiprazole
Number of subjects: 11
Study: 19295332

Group type: EXPERIMENTAL
Intervention: Baseline HRQoL using the Medical Outcome Study HIV Health Survey (MOS-HIV)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Baseline HRQoL using the EQ-5D
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Baseline HRQoL using the Health Utilities Index Mark 3 (HUI3)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Baseline HRQoL using the EQ-5D visual analog scale (EQ-5D VAS)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Baseline HRQoL using standard gamble (SG) technique
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Baseline HRQoL using time trade-off (TTO) technique
Number of subjects: 368
Study: 17576969

Group type: EXPERIMENTAL
Intervention: Morphine with ketamine 1 mg ml(‐1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Morphine 1 mg ml(‐1)
Number of subjects: 50
Study: 15323577

Group type: EXPERIMENTAL
Intervention: Antifracture therapy (specifics not provided)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of multiple vertebral fractures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HR-QOL instruments
Number of subjects: 0
Study: 11713072

Group type: EXPERIMENTAL
Intervention: Intracameral lidocaine (0.5 ml preservative-free 2%)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intracameral saline (0.5 ml sterile saline)
Number of subjects: 15
Study: 9228128

Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg/day)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 7955553

Group type: EXPERIMENTAL
Intervention: Cortisol 200 mg/day over 5 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cortisol cessation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cortisol treatment
Number of subjects: 8
Study: 2885505

Group type: EXPERIMENTAL
Intervention: 20 mg Sb/kg per day for twenty days
Number of subjects: 40

Group type: COMPARATOR
Intervention: 10 mg Sb/kg per day for twenty days
Number of subjects: 40
Study: 31796259

Group type: EXPERIMENTAL
Intervention: Breathing ambient air adjacent to a steel plant
Number of subjects: 59

Group type: COMPARATOR
Intervention: Breathing ambient air 5 km away at a college campus site
Number of subjects: 59
Study: 30968798

Group type: EXPERIMENTAL
Intervention: Computerized cognitive training program (CCT program)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Active control games program
Number of subjects: 69
Study: 29274030

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 463

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 463
Study: 27457369

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT, 0.3 W, 40 s, 4 J/cm²)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Routine postoperative recommendation (ice application)
Number of subjects: 15
Study: 24862638

Group type: EXPERIMENTAL
Intervention: 2 HLA‐mismatched umbilical cord blood (UCB) units
Number of subjects: 2

Group type: COMPARATOR
Intervention: Bone marrow from HLA‐haploidentical relatives
Number of subjects: 2
Study: 22000279

Group type: EXPERIMENTAL
Intervention: Istradefylline 40 mg/day
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Istradefylline 20 mg/day
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Istradefylline 10 mg/day
Number of subjects: 610

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Istradefylline (all doses)
Number of subjects: 610
Study: 21319605

Group type: EXPERIMENTAL
Intervention: Bandwidth knowledge of results (KR) at 5%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bandwidth knowledge of results (KR) at 10%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bandwidth knowledge of results (KR) at 15%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (0% bandwidth KR)
Number of subjects: 0
Study: 18685349

Group type: EXPERIMENTAL
Intervention: Oral and parenteral opioids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose regular opioids (especially sustained-release preparations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other medications (benzodiazepines, nebulised frusemide, selective serotonin reuptake inhibitors)
Number of subjects: 0
Study: 16032487

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 103

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 103
Study: 11844656

Group type: EXPERIMENTAL
Intervention: Cholestin (1.2 g twice daily for 8 weeks)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cholestin (1.2 g twice daily for 2 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cholestin
Number of subjects: 14
Study: 10486647

Group type: EXPERIMENTAL
Intervention: Group 1 (without LVH)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Group 2 (with LVH)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 73
Study: 7480980

Group type: EXPERIMENTAL
Intervention: 2.5 mg rhDNase twice daily for 6 months followed by a 2-week wash-out period, then rhDNase once daily for 18 months
Number of subjects: 52
Study: 1673816

Group type: EXPERIMENTAL
Intervention: Ephedrine 0.07 mg kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Etilefrine 0.03 mg kg‐1
Number of subjects: 30
Study: 7125090

Group type: EXPERIMENTAL
Intervention: Soludactone: 300 mg daily for one week, followed by aldactone orally
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CT examinations
Number of subjects: 20
Study: 31765988

Group type: EXPERIMENTAL
Intervention: Xelox + AZD8931 (20 mg bd with 4/3 schedule)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Xelox only
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Xelox + AZD8931
Number of subjects: 30
Study: 31272421

Group type: EXPERIMENTAL
Intervention: Multi-component implementation support intervention to embed the seven school PA practices of the PA4E1 program.
Number of subjects: 76

Group type: COMPARATOR
Intervention: Usual practice control arm
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Multi-component implementation support intervention
Number of subjects: 76
Study: 28193301

Group type: EXPERIMENTAL
Intervention: risperidone or aripiprazole
Number of subjects: 29

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 29
Study: 25999337

Group type: EXPERIMENTAL
Intervention: Case formulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Homework tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active change strategies
Number of subjects: 0
Study: 24120017

Group type: EXPERIMENTAL
Intervention: Computer-based tool
Number of subjects: 102

Group type: COMPARATOR
Intervention: Manual algorithm
Number of subjects: 102
Study: 22906319

Group type: EXPERIMENTAL
Intervention: Graded-exercise therapy (GET)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Counselling (COUN)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Usual care plus a self-help booklet (BUC)
Number of subjects: 163
Study: 19321313

Group type: EXPERIMENTAL
Intervention: Self-esteem enhancement program for individuals with severe mental illness (case-management care)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Traditional psychiatric care (control group)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Self-esteem enhancement program (overall satisfaction)
Number of subjects: 54
Study: 17299581

Group type: EXPERIMENTAL
Intervention: Phaseolus vulgaris extract (445 mg) taken one tablet per day for 30 days before a carbohydrate-rich meal
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo taken one tablet per day for 30 days before a carbohydrate-rich meal
Number of subjects: 60
Study: 15117912

Group type: EXPERIMENTAL
Intervention: Quinapril (ACE inhibitor)
Number of subjects: 2579
Study: 11606175

Group type: EXPERIMENTAL
Intervention: Vitamin C (1250 mg) and Vitamin E (680 IU) per day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 30
Study: 9540877

Group type: EXPERIMENTAL
Intervention: Omeprazole/amoxicillin for 2 weeks
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Omeprazole for 2 weeks
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Amoxicillin for 2 weeks
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Omeprazole for an additional 2 weeks (study 1)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Placebo for an additional 2 weeks (study 1)
Number of subjects: 233
Study: 8031487

Group type: EXPERIMENTAL
Intervention: Massage device
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dental floss
Number of subjects: 20
Study: 3836875

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Number of subjects: 19
Study: 29658756

Group type: EXPERIMENTAL
Intervention: ProSAAF program
Number of subjects: 346

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 346
Study: 27935990

Group type: EXPERIMENTAL
Intervention: COX‐2 inhibition (2x40mg parecoxib on day of surgery, thereafter 2x200mg celecoxib/day until day five)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: COX‐2 inhibition
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Patients with persistent pain (VAS>30 at 12 months)
Number of subjects: 138
Study: 23461899

Group type: EXPERIMENTAL
Intervention: olanzapine
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 161
Study: 22607100

Group type: EXPERIMENTAL
Intervention: Coupled plasma filtration adsorption (CPFA)
Number of subjects: 14

Group type: COMPARATOR
Intervention: High-volume hemofiltration (HVHF)
Number of subjects: 14
Study: 20557237

Group type: EXPERIMENTAL
Intervention: Azithromycin-artesunate (30 mg/kg per day of azithromycin plus 4 mg/kg per day of artesunate) once daily for 3 days
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control: Artemether (80 mg) plus Lumefantrine (960 mg) twice daily for 3 days
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control: Artemether plus Lumefantrine
Number of subjects: 228
Study: 18534016

Group type: EXPERIMENTAL
Intervention: ACZ885 10 mg/kg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: ACZ885
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 18991519

Group type: EXPERIMENTAL
Intervention: Reiki treatment (twice-weekly for 8 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Touch treatment (twice-weekly for 8 weeks)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Distant therapy (twice-weekly for 8 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham control (twice-weekly for 8 weeks)
Number of subjects: 100
Study: 15149781

Group type: EXPERIMENTAL
Intervention: Hexavalent DTPa‐HBV‐IPV/Hib vaccine (Infanrix hexa)
Number of subjects: 2163

Group type: COMPARATOR
Intervention: Separate administration of DTPa‐IPV/Hib and HBV vaccines
Number of subjects: 2163
Study: 11054323

Group type: EXPERIMENTAL
Intervention: Tamoxifen (oral administration)
Number of subjects: 21
Study: 9352390

Group type: EXPERIMENTAL
Intervention: Test preparation (180 mg diltiazem-HCl)
Number of subjects: 20
Study: 1378786

Group type: EXPERIMENTAL
Intervention: Intravenous gallopamil 0.03 mg/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3516406

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Pizotifen
Number of subjects: 27
Study: 31567658

Group type: EXPERIMENTAL
Intervention: BearStand behavioral intervention group
Number of subjects: 52
Study: 29540123

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate combined with oral nimodipine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 26285807

Group type: EXPERIMENTAL
Intervention: Adjunctive systemic antibiotics
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Local use of chlorhexidine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgical therapy without adjunctive treatment
Number of subjects: 100
Study: 25388526

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at 90 Hz for 20 minutes daily for 12 months
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at 30 Hz for 20 minutes daily for 12 months
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group (no WBV)
Number of subjects: 202
Study: 21827635

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) infusion during exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control, CON) infusion during exercise
Number of subjects: 0
Study: 19212238

Group type: EXPERIMENTAL
Intervention: Laser-Lok (LL) implant
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control implant
Number of subjects: 15
Study: 17513982

Group type: EXPERIMENTAL
Intervention: Concerta
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: MetadateCD/Equasym XL
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 15292287

Group type: EXPERIMENTAL
Intervention: Additional morning dose of hydrocortisone
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 11420801

Group type: EXPERIMENTAL
Intervention: Peer-led AIDS education
Number of subjects: 0
Study: 10193287

Group type: EXPERIMENTAL
Intervention: Xenon (10, 20, 30 and 40%)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (15, 30, 45 and 60%)
Number of subjects: 12
Study: 8164045

Group type: EXPERIMENTAL
Intervention: 1 mg/kg isotretinoin daily for 6 months
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo daily for 6 months
Number of subjects: 86
Study: 3284481

Group type: EXPERIMENTAL
Intervention: Day case surgery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Inpatient surgery
Number of subjects: 70
Study: 29127533

Group type: EXPERIMENTAL
Intervention: Ontuxizumab 2 mg/kg
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Ontuxizumab 4 mg/kg
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Ontuxizumab (both doses)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 76